460 related articles for article (PubMed ID: 31474332)
1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
[TBL] [Abstract][Full Text] [Related]
2. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis.
Fitzpatrick D; Pirie K; Reeves G; Green J; Beral V
PLoS Med; 2023 Mar; 20(3):e1004188. PubMed ID: 36943819
[TBL] [Abstract][Full Text] [Related]
3. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
[TBL] [Abstract][Full Text] [Related]
4. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.
; Beral V; Gaitskell K; Hermon C; Moser K; Reeves G; Peto R
Lancet; 2015 May; 385(9980):1835-42. PubMed ID: 25684585
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer and hormone-replacement therapy in the Million Women Study.
Beral V;
Lancet; 2003 Aug; 362(9382):419-27. PubMed ID: 12927427
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
Beral V; Reeves G; Bull D; Green J;
J Natl Cancer Inst; 2011 Feb; 103(4):296-305. PubMed ID: 21278356
[TBL] [Abstract][Full Text] [Related]
9. Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study.
Salagame U; Banks E; Sitas F; Canfell K
Int J Cancer; 2016 Apr; 138(8):1905-14. PubMed ID: 26599391
[TBL] [Abstract][Full Text] [Related]
10. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Jones ME; Schoemaker MJ; Wright L; McFadden E; Griffin J; Thomas D; Hemming J; Wright K; Ashworth A; Swerdlow AJ
Br J Cancer; 2016 Aug; 115(5):607-15. PubMed ID: 27467055
[TBL] [Abstract][Full Text] [Related]
11. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy and women's health: An umbrella review.
Zhang GQ; Chen JL; Luo Y; Mathur MB; Anagnostis P; Nurmatov U; Talibov M; Zhang J; Hawrylowicz CM; Lumsden MA; Critchley H; Sheikh A; Lundbäck B; Lässer C; Kankaanranta H; Lee SH; Nwaru BI
PLoS Med; 2021 Aug; 18(8):e1003731. PubMed ID: 34339416
[TBL] [Abstract][Full Text] [Related]
16. Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A; Lee J
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004143. PubMed ID: 28093732
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.
Reeves GK; Beral V; Green J; Gathani T; Bull D;
Lancet Oncol; 2006 Nov; 7(11):910-8. PubMed ID: 17081916
[TBL] [Abstract][Full Text] [Related]
19. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet Oncol; 2012 Nov; 13(11):1141-51. PubMed ID: 23084519
[TBL] [Abstract][Full Text] [Related]
20. Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study.
Velentzis LS; Banks E; Sitas F; Salagame U; Tan EH; Canfell K
PLoS One; 2016; 11(3):e0146494. PubMed ID: 27008039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
